Rapid growth of expectorant Market: over 12 billion yuan in scale, 90% of the top ten varieties

With the development of the aging society, the market of antitussive and expectorant drugs is increasing According to the data of MI Nei net HDM system, in 2016, the market scale of respiratory system drugs in public hospitals in key cities in China reached 4.66 billion yuan, an increase of 13.66% over the previous year, showing a rapid growth trend Panorama: according to the report on nutrition and chronic diseases of Chinese residents (2015) issued by China CDC and other departments organized by the national health and Family Planning Commission, the mortality rate of respiratory diseases is 68 / 100000, and the prevalence rate of COPD in Chinese people aged 40 and over is 9.9% According to China's CMH data, in 2015, the market scale of respiratory system medicine terminal reached 124.5 billion yuan, and in 2016, it increased to 139.5 billion yuan, an increase of 12.05% over the previous year In the respiratory system drug terminal market, antitussive and expectorant drugs accounted for 38.96% On the whole, the antitussive and expectorant drugs market in China presents a situation in which Chinese and Western medicines compete Antitussive and expectorant Chinese patent medicine has the characteristics of good antitussive and expectorant effect, good taste and low toxic and side effects It is more favored in China, and its brand is deeply rooted in the people's mind, but the long course of medication is its deficiency In the past two years, chemical drugs have been very popular The market share of Chinese and Western medicine is almost equal In 2017, 171 respiratory drugs were included in the national medical insurance drug catalog, including 92 compound OTC drugs for relieving cold and 79 prescription drugs for respiratory system 16 antitussive and expectorant drugs were collected, accounting for 62.5% of the total Among them, Eucalyptus ningpinene enteric coated gel and fludostane oral regular release preparation are new varieties According to the data of HDM system, in 2016, the amount of expectorant and antitussive drugs used by public hospitals in key cities in China was 1.562 billion yuan, an increase of 13.74% over the previous year On the market of expectorants, the TOP 10 drugs are ambroxol, acetylcysteine, Eucalyptus Linpin enteric soft capsule, bromhexin, fluestan, ambroxol, yuphen methylephedrine, erdostensin, fufangfulkeding, cefaclor bromhexin The TOP 5 varieties have entered the national medical insurance drug catalog Top 10 expectorants account for nearly 90% of the market Data analysis shows that expectorants have become one of the rapidly growing drug categories in China and one of the most promising drug markets in the next 10 years In 2016, the market scale of expectorant drugs in six major markets, including urban public hospitals, county-level public hospitals, urban community health care, township hospitals, physical pharmacies and online stores, exceeded 12 billion yuan The total market of Eucalyptus ningpinene capsule is over 1 billion yuan It is the exclusive product of Beijing Jiuhe Pharmaceutical Co., Ltd and its trade name is "chenuo" In 1998, it won the first prize of scientific and technological progress of Chinese Academy of Medical Sciences and belongs to the national class II new drug In 2005, it was approved by CFDA, and in 2007, children's clothing was approved for marketing Eucalyptus, Caragana and pinene enteric coated capsules have the same therapeutic effect as the standard Myrtle oil (trade name: ginoton) produced by Germany Baoshi Jiada pharmaceutical factory With the expansion of the market of Eucalyptus and ningpinene, the import standard Myrtle oil has been withdrawn from the Chinese market after the expiry of the registration approval At present, Beijing Jiuhe Pharmaceutical Co., Ltd is the exclusive variety in China In 2017, it was included in the new national medical insurance drug catalog According to the data of HDM system, in 2016, the drug amount of Eucalyptus ningpinene in public hospitals in key cities in China was 137 million yuan, an increase of 42.44% over the previous year In fact, Eucalyptus limonensis has entered the medical insurance drug catalogue of many provinces and cities It is predicted that the total market sales of Eucalyptus limonensis will exceed 1 billion yuan at the retail price, and it will be available in the future Ambroxol, 54% of which is made in China, is a new active metabolite of bromhexin It can promote the formation of pulmonary surfactant, and it is a kind of phlegm dissolving drug, which can relieve cough and dyspnea, and is conducive to the discharge of airway secretion According to IMS global top 500 best selling drug data, in 2015, the market size of Mucosolvan sold by Germany's bringer Ingelheim and Japan's imperial was 288 million US dollars, an increase of 2.44% over the previous year In the 1990s, ambroxol of bringer Ingelheim company entered the market of our country, with the trade name of ambroxol Then the domestic ambroxol production went on the market By April 2017, CFDA had approved 192 ambroxol production approvals, and 8 enterprises, including Changzhou No.4 pharmaceutical, Hengrui pharmaceutical, Beijing Taiyang pharmaceutical, Luoxin pharmaceutical, Yangzhou No.3 pharmaceutical, Shaanxi Hanjiang pharmaceutical, southwest synthetic and Petrochemical Group Ouyi pharmaceutical, had been approved to produce ambroxol APIs So far, there are 70 manufacturers of ambroxol in China, and 13 dosage forms have been approved, including tablets, sustained-release tablets, dispersible tablets, effervescent tablets, orally disintegrating tablets, sustained-release capsules, granules, oral solutions, syrups, injections, powder injections for injection, sodium chloride injection, glucose injection In addition, ambroxol, the ambroxol brand of Hong Kong Aomei pharmaceutical factory, was registered According to the data of HDM system, the amount of ambroxol used in public hospitals in key cities in 2016 was 774 million yuan, down 2.58% from the previous year, but ambroxol still accounts for half of the expectorant drug market At present, domestic ambroxol accounts for 54% of the total, and ambroxol accounts for 46.10% The domestic ambroxol top 5 is: Changzhou four drugs account for 15.50%, Shenyang Xinma 12.86%, Tianjin Pharmaceutical Institute 7.29%, Yunnan Longhai 3.27%, Hainan Weikang 2.86% Data shows that in 2016, ambroxol injection accounted for 91.67% of the market in domestic sample hospitals, and ambroxol oral tablets, solutions, capsules and granules accounted for 8.33% Acetylcysteine, mainly injection, is a classical basic drug for resolving phlegm With the extensive use and further research, it is further recognized that acetylcysteine can break the disulfide bond of glycoprotein polypeptide chain in sputum, decompose glycoprotein and liquefy mucus At the same time, it can also crack DNA, which has strong antioxidant effect and promotes the formation of pulmonary surfactant According to the data of HDM system, the amount of acetylcysteine used in public hospitals in key cities in 2016 was 318 million yuan, an increase of 68.59% over the previous year The acetylcysteine effervescent tablets and inhalation solutions of Zambon, Italy, have been registered with CFDA under the trade name Fluimucil There are 6 enterprises approved to use domestic acetylcysteine for expectorant indications In 2016, among the top 5 manufacturers of acetylcysteine, Hangzhou Minsheng injection "asixintai" accounted for 63.13%, zambang injection "FuLuShi" accounted for 22.40%, Guangdong renrenkang capsule "yiweishi" accounted for 7.15%, Jinhua Kangenbei effervescent tablets accounted for 5.64%, and Guangdong Baiao Granule "Aoyuan No.1" accounted for 1.49% The monopoly of bromohexin injection has a strong effect on sputum dissolution and sputum excretion At present, the new domestic bromhexin preparations have all covered the hospital terminal market CFDA has approved 41 enterprises to produce new bromhexin tablets and 16 enterprises to produce new bromhexin injections According to the data of HDM system, in 2016, the amount of new brominated drugs used in public hospitals in key cities in China was 134 million yuan, an increase of 32% over the previous year In the domestic sample hospital market, Jincheng Haisi, Jiangxi Kelun, Shijiazhuang No.4, Anhui Fengyuan and Guorui accounted for 30.12%, 24.04%, 16.39%, 10.42% and 6.43% respectively The price of bromhexine tablets is low, the competition is fierce, and its share is small; the proportion of bromhexine injections is 99.45% In the market of bromhexin injection, the powder injection of jinchenghaisi, the injection of bromhexin glucose of Jiangxi Kelun and Shijiazhuang four drugs monopolized the market, with high market concentration The top five drugs in the expectorant market are new drugs in the national medical insurance drug catalog in 2017, belonging to cysteine derivatives, which are new expectorant and mucosolvic drugs Fuduositan is developed and manufactured by SSP company and welside company of Japan It was first listed in Japan on December 17, 2001 The indications of the drug cover almost all respiratory diseases, including bronchitis After 2008, CFDA approved the production and listing of six fudosten oral preparations, including Sichuan Kelun, Zhengda qingqingbao, Jiangsu Zhengda Fenghai, Tianfang pharmaceutical, Disha pharmaceutical and Yichang dongyangguang Changjiang pharmaceutical, but no imported drugs were listed in China According to the data of HDM system, in 2016, the amount of fludostane used in public hospitals in key cities in China exceeded 33.3 million yuan, an increase of 24.29% over the previous year; the overall market size in China was about 300 million yuan The top three are: Sichuan Kelun's products account for 64.80%, Disha pharmaceutical's products account for 21.45%, Jiangsu Zhengda Fenghai's products account for 12.35%, and other companies' products account for 1.4% In terms of dosage form, 53.73% was capsule and 46.27% was tablet